Korean J Anat.  2004 Dec;37(6):549-555.

Effects of Sulphasalazine and Glucocorticoid on the Regulation of CCL20 Gene Expression in the Peripheral Blood Cells of Korean Patients with Ulcerative Colitis

• Choi SC
• Nah YH
• Chung YT
• Han WC
• Lee MS
• Jun CD

Abstract

Discovery of Nod2 has brought to light the significance of mononuclear cells as well as epithelial cells in inflammatory bowel disease (IBD) pathogenesis. Similarly, CCL20 is expressed in both mononuclear cells and epithelial cells and is likely to link innate and acquired immunity. We therefore asked whether CCL20 expression is altered in the peripheral blood mononuclear cells (PBMCs) from patients with ulcerative colitis (UC), a major type of IBD in Korea, and is correlated with the disease activity. The expression levels of CCL20 mRNA were significantly high in the PBMCs from the patients with UC. CCL20 protein expression was also up-regulated in the mucosal epithelium in UC but not in normal controls. Interestingly, however, disease activity index (DAI) revealed that untreated UC groups express higher expression levels of CCL20 mRNA than treated UC groups, implying that CCL20 may be a potential target for the anti-inflammatory treatments. In an agreement with this, three months follow up study revealed that the UC patients who were treated with 5-amino salicylic acid (5-ASA) and glucocorticoid showed dramatic decrease in their CCL20 mRNA levels as compared to untreated ones. Moreover, TNF-alpha-or IL-1beta-induced CCL20 secretion in human epithelial HT-29 cells was significantly diminished by the treatment with 5-ASA and/or dexamethasone, suggesting that CCL20 may be one of the central targets of the anti-inflammatory drugs. Collectively, these results suggest that CCL20 expression in UC may be associated with altered immune and inflammatory responses in the blood as well as the intestinal mucosa and further implied a potential for CCL20 as an important diagnostic marker for UC.

Keyword

Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; CCL20; Anti-inflammatory agent

MeSH Terms

Adaptive Immunity
Blood Cells*
Colitis, Ulcerative*
Crohn Disease
Dexamethasone
Epithelial Cells
Epithelium
Follow-Up Studies
Gene Expression*
HT29 Cells
Humans
Inflammatory Bowel Diseases
Intestinal Mucosa
Korea
RNA, Messenger
Salicylic Acid
Sulfasalazine*
Ulcer*
Dexamethasone
RNA, Messenger
Salicylic Acid
Sulfasalazine